congenital enzyme disorder
Vimizin shown green light
February 19, 2014Research and Development, Sales and Marketing BioMarin, FDA, congenital enzyme disorder, vimizin
Regulators have shown the green light to BioMarin Pharmaceutical’s Vimizim as a treatment for a rare enzyme deficiency which affects …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
